COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #31
Source   Share   Tweet
See all 146 studies
Late treatment study
Rosenberg et al., JAMA, May 11, 2020, doi:10.1001/jama.2020.8630 (Peer Reviewed)
Association of Treatment With Hydroxych loroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Restrospective observational late stage study showing no significant differences but calling for clinical trials.
Zervos et al. [1] point out serious limitations that they say should be corrected on the record: patients receiving HC Q with or without AZ were overall sicker on presentation and had multiple other risk factors including much higher risk based on ethnicity; patients receiving HC Q were more likely to be obese, diabetic, have chronic lung disease, and cardiovascular conditions; yet these sicker patients had approximately the same mortality rates compared to patients with a milder course of the disease and less risk factors. However, the authors conclude that "there are no significant benefits." It is noteworthy that HC Q was associated with a significant survival benefit in a larger cohort of patients from New York City as reported by Mikami et al [2].
death, ↑35.0%, p=0.31
death, ↑8.0%, p=0.79
Source   Share   Tweet
See all 146 studies
Please send us corrections, updates, or comments.